1. Home
  2. AGIO vs LGIH Comparison

AGIO vs LGIH Comparison

Compare AGIO & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • LGIH
  • Stock Information
  • Founded
  • AGIO 2007
  • LGIH 2003
  • Country
  • AGIO United States
  • LGIH United States
  • Employees
  • AGIO N/A
  • LGIH N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • LGIH Homebuilding
  • Sector
  • AGIO Health Care
  • LGIH Consumer Discretionary
  • Exchange
  • AGIO Nasdaq
  • LGIH Nasdaq
  • Market Cap
  • AGIO 1.4B
  • LGIH 1.4B
  • IPO Year
  • AGIO 2013
  • LGIH 2013
  • Fundamental
  • Price
  • AGIO $33.97
  • LGIH $55.21
  • Analyst Decision
  • AGIO Buy
  • LGIH Hold
  • Analyst Count
  • AGIO 6
  • LGIH 5
  • Target Price
  • AGIO $58.60
  • LGIH $92.25
  • AVG Volume (30 Days)
  • AGIO 529.1K
  • LGIH 350.3K
  • Earning Date
  • AGIO 07-31-2025
  • LGIH 07-29-2025
  • Dividend Yield
  • AGIO N/A
  • LGIH N/A
  • EPS Growth
  • AGIO N/A
  • LGIH N/A
  • EPS
  • AGIO 11.45
  • LGIH 7.76
  • Revenue
  • AGIO $37,035,000.00
  • LGIH $2,163,167,000.00
  • Revenue This Year
  • AGIO $22.30
  • LGIH $1.29
  • Revenue Next Year
  • AGIO $219.19
  • LGIH $29.49
  • P/E Ratio
  • AGIO $3.00
  • LGIH $7.18
  • Revenue Growth
  • AGIO 25.96
  • LGIH N/A
  • 52 Week Low
  • AGIO $23.42
  • LGIH $47.17
  • 52 Week High
  • AGIO $62.58
  • LGIH $125.83
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 52.40
  • LGIH 50.71
  • Support Level
  • AGIO $32.53
  • LGIH $48.54
  • Resistance Level
  • AGIO $34.34
  • LGIH $52.61
  • Average True Range (ATR)
  • AGIO 1.28
  • LGIH 2.14
  • MACD
  • AGIO -0.31
  • LGIH 0.51
  • Stochastic Oscillator
  • AGIO 20.98
  • LGIH 52.95

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. They have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.

Share on Social Networks: